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OBJECTIVE: Post-menopausal osteoporosis has signiﬁcant
health care costs and impacts quality of life. The objective of this
analysis was to assess the cost-effectiveness of risedronate com-
pared to calcium + vitamin D, etidronate, alendronate, and 
ibandronate in high-risk osteoporotic patients in Germany.
METHODS: A validated model (Tosteson, 2001) was used to
estimate the impact of therapy on hip and vertebral fractures,
costs, and quality adjusted life years (QALYs). The analysis
included women 70 years with a BMD T-Score of <-2.5 and a
history of vertebral fracture, treated over 3 years. The model
further simulated downstream costs and QALYs for a 10-year
period. Country-speciﬁc data included general population mor-
tality, hip and hospitalized vertebral fracture rates, fracture costs,
and daily drug prices (risedronate €1.50; etidronate €1.17; alen-
dronate €1.50; ibandronate €1.38). Ibandonate price based on
U.S. pricing relative to risedronate, as German pricing not avail-
able. Hip and vertebral fracture reductions (risedronate 60%,
49%; etidronate 34%, 37%; alendronate 51%, 47%; iban-
dronate 0% [No efﬁcacy demonstrated], 52% [Using 62% for
efﬁcacy does not change results]) were based on published clin-
ical trials. RESULTS: In a cohort of 1000 postmenopausal
women with 3 years of treatment the model predicted the fol-
lowing costs, total hip and hospitalized vertebral fractures and
QALYs: risedronate (€8.22M, 139, 5451); alendronate (€8.41M,
142, 5447); etidronate (€8.42M, 149, 5441); ibandronate
(€9.33M, 159, 5429); calcium + vitamin D (€7.91M, 164, 5427).
All bisphosphonates were dominated by risedronate, which was
less costly and had better outcomes. Risedronate had a cost per
fracture averted of €12,389 and a cost per QALY gained of
€13,253, compared to calcium + vitamin D. CONCLUSIONS:
The analysis favors the adoption of risedronate therapy for the
treatment of postmenopausal osteoporosis compared to other
bisphosphonates.
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OBJECTIVES: The aim of the study is to show the utilization of
hip-prosthesis implantations in Hungary according to age groups
and geographical regions. METHODS: In this retrospective
study the data derive from the ﬁnancial database of the National
Health Insurance Fund of Hungary and the database of the Hun-
garian Central Statistical Ofﬁce. For the analysis we used the
International Classiﬁcation of Diseases (ICD) tenth revision and
the surgical codes of the Hungarian Homogenous Disease
Groups related to prosthesis implantations. The study includes
all the hip implantations that occur for the ﬁrst time in the year
of 2002 as a one side primary prosthesis, regardless of the status
of the opposite hip (such as the coxarthrosis, primary treatment
of hip fractures or their prosthesis after changing the methods,
other problems). The study does not include the implantation of
hip prosthesis on the opposite side within one year, and the pros-
thesis implanted earlier but having been replaced because of any
reasons. RESULTS: The total number of patients fulﬁlled the cri-
teria mentioned above were 8019. The average number of
patients with hip prosthesis (either hemi or total) per 10,000
populations was 7.90. According to age-groups: age 10–19: 0.03
case, age 20–29: 0.18 case, age 30–39: 1.01 case, age 40–49:
4.89 cases, age 50–59: 10.46 cases, age 60–69: 23.51 cases, age
70–79: 32.72 cases, aged over 80: 25.21 cases. The number 
of patients having prosthesis according to the geographical
regions per 10,000 population: Central-Hungary: 8.72, 
Central-Transdanubia: 7.87, Western-Transdanubia: 8.35,
Southern-Transdanubia: 8.86, Southern-Greatplane: 8.7, 
Northern-Hungary: 6.89, Northern-Greatplane: 5.69. CON-
CLUSION: We realized signiﬁcant regional differences in the uti-
lization of hip implantations. Further studies are needed to
explore the causes and factors inﬂuencing the regional differ-
ences.
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Numerous studies have directly assessed patient preferences for
different treatments, but have provided little evidence support-
ing the validity of their preference questionnaires. OBJECTIVE:
The objective of this study was to perform a qualitative analysis
of patients’ perspectives of an Osteoporosis Treatment Prefer-
ence Questionnaire (OTPQ) comparing preferences for once-
monthly versus once-weekly administration of bisphosphonate
therapy for osteoporosis. METHODS: The OTPQ contains one
question directly eliciting dosing schedule preference, two ques-
tions with multiple items assessing possible reasons for the stated
preferences, and a convenience question. Because the OTPQ
comprises no multi-item scales and thus psychometric evaluation
analyses would be limited, a cognitive debrieﬁng study was con-
ducted as the primary method of assessing validity. This study
involved semi-structured one-on-one telephone interviews with
a convenience sample of women currently receiving bisphos-
phonate therapy for postmenopausal osteoporosis. They com-
pleted the OTPQ at the beginning of the phone call and
subsequently were interviewed about the mental process
involved in responding to the questions, their interpretation of
the items, and how responses were selected. RESULTS: Twenty
women completed the interviews. The participants were primar-
ily white (85%), had a mean age of 63.7 years, and most were
taking weekly alendronate (85%). In general, participants
believed that the OTPQ was easy to understand and appropri-
ate for assessing patient preferences for once-monthly versus
once-weekly osteoporosis treatment. One item was not inter-
preted in a consistent manner among 9 of the ﬁrst 15 partici-
pants. As a result, this item was revised and tested with the
remaining ﬁve participants. These additional interviews afﬁrmed
that the revision clariﬁed the intent of the item. No additional
modiﬁcations to the questionnaire were required based on the
ﬁndings. CONCLUSIONS: This cognitive debrieﬁng study pro-
vided a strong foundation for the content validity of the OTPQ.
Such studies should be a critical component in the development
of preference questionnaires.
